• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Aug. 29, 2016

View Archived Issues

Financings

Sophiris Bio Inc., of San Diego, closed its previously disclosed public offering of 6.5 million of its common shares and related warrants to purchase 4.87 million of its common shares with an exercise price of $4 per share, offered at a combined price of $4 per share and related warrant, for gross proceeds of $26 million. Read More

Other news to note

Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, launched an initiative to increase access to its products in territories and therapeutic areas with the highest unmet need, including emerging health care systems in Latin America, Southeast Asia and Africa. Read More

In the clinic

Cempra Inc., of Chapel Hill, N.C., highlighted the publication of an article about Solitaire-IV, its pivotal phase III study of solithromycin for the treatment of community-acquired bacterial pneumonia (CABP), in the journal Clinical Infectious Diseases. Read More

Bench Press: BioWorld looks at translational medicine

Separating delta opioid receptors from the G protein-coupled receptor kinase 2 (GRK2), which normally associates with it in cell membranes, allowed agonists to have an analgesic effect via the delta receptor. Read More

Regulatory front

As a further safety measure against the emerging Zika virus outbreak, the FDA issued a revised guidance recommending universal testing of donated whole blood and blood components for Zika virus in the U.S. and its territories. Read More

Discovery may eradicate colorectal CSCs

HONG KONG – A novel small-molecule Wnt inhibitor possessing the potential to eradicate colorectal cancer stem cells (CSCs) may provide a new therapeutic option for patients with drug-refractory colorectal cancer, a team of Japanese researchers reported in the Aug. 26, 2016, edition of Nature Communications. Read More

Cardiocell’s stem cells via IV might be the answer in heart failure

Some chronic heart failure (HF) patients given an intravenous injection (IV) of specially prepared stem cells during a small phase IIa study saw significant functional and quality of life improvements associated with the treatment, Cardiocell LLC reported during the European Society of Cardiology Congress in Rome. Read More

Poietis’ 3-D technology bioprints human tissue

Pessac, France-based Poietis SAS is developing a platform of laser-assisted 3-D bioprinting for the cosmetics and pharmaceuticals industries as well as regenerative medicine centers. The French startup is preparing to target the European, North American and Japanese markets with its print-manufactured living tissues. Read More

Biothera finds serendipity in immuno-oncology

Biothera Pharmaceuticals Inc. is hardly a traditional biopharma newco. The company’s core beta glucan immunomodulator technology, developed by researchers at the Massachusetts Institute of Technology, was picked up following the 1999 liquidation of Alpha-Beta Technology Inc., which had sought to advance the platform to treat bacterial infections. Read More

Don’t cry for Ampligen yet: Argentina OKs CFS therapy, Hemispherx U.S. hope alive

Hemispherx Biopharma Inc. CEO Thomas Equels told BioWorld Today that the approval in the Argentine Republic of rintatolimod for severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is “the opening of a door” to the rest of the world, which is waking up to the reality of the disease as research picks up momentum. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • White puzzle pieces on blue background

    Highridge sells bone healing business to Avista

    BioWorld MedTech
    In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division to Avista Healthcare Partners. The...
  • Pill with British pound sign

    Pharma execs speak out: UK pricing rebates scare investors

    BioWorld
    The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...
  • DNA mutations or genetic disorder concept art

    Regenxbio’s Duchenne gene therapy data positive as shares falter

    BioWorld
    Regenxbio Inc.’s gene therapy in treating Duchenne muscular dystrophy (DMD) produced positive initial phase I/II results from its first five patients. However,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe